NasdaqGS:LENZPharmaceuticals
LENZ Therapeutics (LENZ) Loss Deepens As VIZZ Launch Tests Bullish Growth Narratives
Financial results set the stage for LENZ Therapeutics (LENZ)
LENZ Therapeutics (LENZ) has reported fresh numbers for FY 2025, with third quarter revenue of US$12.5 million and a loss per share of US$0.59, as net income excluding extra items came in at a loss of US$16.7 million. The company’s revenue moved from US$0 in the second quarter of 2024 to US$12.5 million in the third quarter of 2025. Over the same period, basic EPS shifted from a loss of US$0.38 to a loss of US$0.59. This provides a...